Faes Farma (BME:FAE) Second Quarter 2025 Results
Key Financial Results
- Revenue: €154.4m (up 15% from 2Q 2024).
- Net income: €24.0m (down 14% from 2Q 2024).
- Profit margin: 16% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Faes Farma Earnings Insights
Looking ahead, revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in Europe.
Performance of the market in Spain.
The company's shares are down 3.8% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Faes Farma you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BME:FAE
Faes Farma
Researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally.
Undervalued with adequate balance sheet.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives
Bajaj Auto has seen a correction in its stock price after a strong rally, making it an attractive opportunity for investors.

Aussie’s Barton Gold, No Debt Miner with 1 Mill That Changes Everything

ASIC is a technology-differentiated E&S insurer compounding book value with a structurally improving combined ratio
Popular Narratives
NVIDIA will see a profit margin surge of 55% in the next 5 years

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks


